paroxetine / Generic mfg. - LARVOL DELTA

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. (PubMed, BMJ) - "The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants."

Adverse events • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system. (PubMed, Eur Arch Psychiatry Clin Neurosci) - "SSRIs showed homogeneous adverse event reporting patterns, with relatively few differences in disproportional reporting between individual drugs. These results reinforce the importance of continuous pharmacovigilance monitoring."

Adverse events • Journal • CNS Disorders • Mental Retardation • Pain • Psychiatry • ROR1

From Falls to Frontal Lobe Dysfunction: A Case Report on the Neurodevelopmental Impact of Pediatric Traumatic Brain Injury. (PubMed, Case Rep Psychiatry) - "This approach utilized mood stabilizers, specifically lithium and valproic acid, alongside the selective serotonin reuptake inhibitor (SSRI) paroxetine...This case highlights the importance of considering long-term neurological consequences of TBI, even in the absence of immediate symptoms. It also illustrates the potential value of tailored pharmacological management within a broader multidisciplinary approach."

Journal • CNS Disorders • Pediatrics • Vascular Neurology

A longitudinal case report illustrating diagnostic complexity among overlapping sleep-wake phenotypes. (PubMed, Sleep Med) - "Positive airway pressure therapy successfully treated sleep disordered breathing while pitolisant and solriamfetol produced the most durable improvement in daytime sleepiness. Together melatonin plus clonazepam reduced parasomnia frequency and severity. Several other agents (including prazosin, sodium oxybate, paroxetine, and modafinil) were tried and discontinued for limited benefit or adverse effects...The observation may justify further study of metabolic and incretin-related pathways in sleep-related eating behaviors. Overall, this case highlights the complexity of overlapping sleep-wake disorders, the need for individualized pharmacologic sequencing, and a potential emerging role for GLP-1 agonists in SRED."

Journal • CNS Disorders • Delayed Sleep Phase Disorder • Excessive Daytime Sleepiness • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Sleep Wake Cycle Disorder

NEUROMODULATION OF REFRACTORY CHRONIC COUGH IN DIPNECH: A CASE OF PAROXETINE RESPONSE (CHEST 2026) - No abstract available

Clinical • Chronic Cough • Cough • Respiratory Diseases

Association between cognitive coping therapy coupled with paroxetine and clinical outcomes in patients with generalized anxiety disorder: A retrospective study. (PubMed, Pharmacol Biochem Behav) - "In this retrospective study, compared with paroxetine alone, cognitive CCT combined with paroxetine was associated with greater improvements in anxiety symptoms, headache severity, sleep quality, coping styles, plasma neurotransmitter levels, and quality of life among patients with GAD."

Clinical data • Journal • Retrospective data • CNS Disorders • General Anxiety Disorder • Mood Disorders • Pain • Psychiatry

A Phase I Study of NS-079 in Healthy Participants (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: NeuShen Therapeutics | Not yet recruiting ➔ Recruiting | Trial primary completion date: Jul 2026 ➔ Feb 2027

Enrollment open • Trial primary completion date

LYMPHODEP: Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Germans Trias i Pujol Hospital | Trial completion date: Jul 2027 ➔ Jul 2026 | Trial primary completion date: Dec 2026 ➔ Jun 2026 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

Antidepressant composition change before bipolar disorder diagnosis among patients initially diagnosed with major depressive disorder. (PubMed, J Affect Disord) - "The duloxetine composition-change signal was not confined to the immediate 180-day prediagnostic period, whereas paroxetine and escitalopram signals were observed only in that period. These diagnosis-preceding prescribing patterns remain susceptible to protopathic bias and should not be interpreted as causal medication effects."

Journal • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK. (PubMed, Lancet Psychiatry) - "CYP2D6 PM status was consistently associated with increased risk of venlafaxine treatment failure in two large, real-life cohorts, suggesting that pre-emptive genotyping could facilitate personalised venlafaxine therapy."

Journal • Observational data • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry • CYP2C19

Psychotropic Polypharmacy in Alzheimer's Disease: A Potentially Inappropriate Medication Perspective in Older Adults. (PubMed, Curr Alzheimer Res) - "This review specifically examines anticholinergic drugs, antipsychotics, benzodiazepines and Z-drugs, tricyclic antidepressants, and select newer antidepressants-including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), mirtazapine, trazodone, and paroxetine-guided by the 2023 American Geriatrics Society (AGS) Beers Criteria®. Current evidence indicates that these medications may contribute to cognitive decline through anticholinergic burden, sedation, and pharmacodynamic interactions with cholinesterase inhibitors, such as donepezil and memantine...This study also summarizes current nonpharmacological strategies and proposes a structured clinical medication review framework. Overall, this review highlights the importance of minimizing inappropriate psychotropic use in AD, prioritizing non-pharmacological interventions, and conducting individualized risk-benefit assessments in clinical practice."

Journal • Alzheimer's Disease • Anesthesia • CNS Disorders • Dementia • Psychiatry

SSRI Use in Irritable Bowel Syndrome and Its Impact on Disease Outcomes: A Propensity-Matched Real-World Cohort Study (ACG 2026) - "Cohort 1 received an SSRI (sertraline, escitalopram, citalopram, fluoxetine, or paroxetine) within 1 year of diagnosis without concurrent TCA use. Post-matching cohorts were well-balanced (79.7% female, ~80% White). SSRI use was associated with lower functional symptom persistence (57.0% vs. 60.7%; RR 0.94, 95% CI 0.93-0.94; p< 0.001; median time-to-recurrence 589 vs."

Clinical • Real-world • Real-world evidence • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Mood Disorders • Ulcerative Colitis

Bridging Psychiatry and Primary Care: A Biologically Informed Suicide Prevention Model (WFSBP 2026) - "Case A — escitalopram brand switch in a stably remitted patient producing emotional blunting and partial efficacy loss despite identical labelled dose, traceable to altered dissolution and excipient-mediated changes in CNS serotonergic tone...Case C — paroxetine switch precipitating SSRI discontinuation syndrome ("electric shocks," dizziness, anxiety) misdiagnosed as relapse: the patient was relabelled rather than re-formulated. Case D — clozapine post-procurement change producing sedation and hypersalivation reframed by clinicians as "tolerance loss." The common pathophysiology across signals is peak–trough variability, altered Cmax / Tmax, excipient-driven absorption variance, and polymorphic dissolution behaviour — none of which are captured by single-dose healthy-volunteer bioequivalence studies. The orphan-comparator problem is introduced (e.g., lemborexant has only one marketed brand in India: tolerability change cannot be scientifically..."

Clinical • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry

CYP2D6 Allele and Metabolizer Phenotype Distribution in a Central Indian Depression Cohort: Interim Pharmacogenetic Findings (WFSBP 2026) - "These findings have direct implications for antidepressant prescribing. CYP2D6 PMs may experience higher exposure and adverse effects with paroxetine, fluvoxamine, venlafaxine, TCAs, and vortioxetine, while UMs risk subtherapeutic response. The substantial IM proportion may have altered dose requirements."

Biomarker • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • CYP2D6

Pharmacotherapeutic considerations for the treatment of post-traumatic stress disorder during and after pregnancy: an update. (PubMed, Expert Opin Pharmacother) - "Therefore, guidelines recommend treatment with sertraline, paroxetine, or venlafaxine. Few medications are recommended for the management of PTSD during pregnancy and lactation. In the future, research must focus on the development of safe and effective interventions to ensure the delivery of inclusive healthcare for women in all life stages."

Journal • Review • CNS Disorders • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Effects of Paroxetine on Cardiovascular Function in Septic Patients (clinicaltrials.gov) - P2 | N=130 | Completed | Sponsor: Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | Recruiting ➔ Completed | N=92 ➔ 130 | Trial completion date: Apr 2025 ➔ Jan 2026 | Trial primary completion date: Mar 2025 ➔ Jan 2026

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Infectious Disease • Septic Shock

Visualizing Vascular Effects of Selective Serotonin Reuptake Inhibitors: An OCT Angiography Perspective. (PubMed, Retina) - "Chronic use of SSRIs has been associated with measurable reductions in retinal vascular density and enlargement of the FAZ, which may reflect microvascular compromise. Escitalopram appears to demonstrate a more pronounced vascular effect in comparison to other selective serotonin reuptake inhibitors SSRIs. These findings highlight the significance of retinal vascular evaluation in patients undergoing long-term SSRI therapy."

Journal • Cardiovascular • Ophthalmology

Lymphocytic Microscopic Colitis Associated with Paroxetine: A Psychiatric Nursing Case Report. (PubMed, J Am Psychiatr Nurses Assoc) - "This case illustrates the importance of psychiatric nursing vigilance for persistent gastrointestinal symptoms in patients receiving serotonergic antidepressants. Recognition of possible medication-associated MC may support timely referral, interdisciplinary collaboration, and individualized psychopharmacologic decision-making."

Journal • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • General Anxiety Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Pain • Psychiatry

Xiaoyao San exerts antidepressant effects via the gut microbiota-brain axis: An integrative fMRI and multiomics study. (PubMed, J Pharm Biomed Anal) - "Mice were treated with XYS at low, medium, and high doses or paroxetine...This study demonstrates that XYS alleviates depression by orchestrating a gut-brain signaling cascade that converges on the PFC to enhance inhibitory synaptic transmission. These findings provide novel and causal mechanistic insights into the brain-gut modulatory action of XYS, offering a comprehensive framework for its therapeutic potential in treating depression."

Journal • CNS Disorders • Depression • Psychiatry • Transplantation • SYP

The impact of fluoxetine on the aversive effects of lysergic acid diethylamide. (PubMed, Exp Clin Psychopharmacol) - "(2025) reported that adverse effects induced by lysergic acid diethylamide (LSD) were reduced by pretreatment with the selective serotonin reuptake inhibitor paroxetine, while "good drug effects" induced by LSD were not. Although there was no overall impact of fluoxetine on LSD, consumption by a subset of subjects in the fluoxetine-LSD group that drank less than the group's mean did not overlap with consumption of subjects drinking less than the mean of the vehicle-LSD group, indicating an attenuating effect of fluoxetine. Future work should assess the generalization of such effects across different psychedelic classes and the neurobiological mediation of the effects with other combinations of antidepressants and psychedelics."

Journal

Effects of antidepressant administration on physical performance and perceived exertion in athletes: systematic review and meta-analysis. (PubMed, Int J Clin Pharm) - "Short-term antidepressant administration in athletes was associated with a small increase in perceived exertion, without consistent impairment in objective physical performance. As the current evidence derives exclusively from male athletes and acute exposure, further research should clarify its relevance to female athletes and to longer-term antidepressant treatment in athletes with depressive disorders."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

Drug-induced dysphagia: Analysis of age and time of onset profiles using a Japanese pharmacovigilance database. (PubMed, Int J Clin Pharmacol Ther) - "Drug-induced dysphagia profiles differ among drugs, particularly in terms of timing of onset and patient age distribution. Therefore, clinicians should consider both the causative drug and the patient's age when monitoring for dysphagia."

Adverse events • Journal • Gastrointestinal Disorder

Study on action mechanism of Dabugan Decoction in rats with chronic unpredictable mild stress by regulating liver-brain 5-HT system (PubMed, Zhongguo Zhong Yao Za Zhi) - "After modeling, the rats were randomly divided into a model group, a paroxetine group(1.8 mg·kg~(-1)), and Dabugan Decoction groups of high(10.8 g·kg~(-1)), medium(5.4 g·kg~(-1)), and low dose(2.7 g·kg~(-1)), with drug intervention lasting for 21 days...Protein expressions of 5-HT_(2A)R, 5-HT_(3A)R, 5-HT_4R decreased in hippocampal tissue(P<0.05 or P<0.01) and significantly increased in liver tissue(P<0.05). These results indicated that Dabugan Decoction can improve anxiety states in rats with CUMS by regulating 5-HT and receptor expression in the liver and hippocampal tissue."

Journal • Preclinical • Mood Disorders • Psychiatry

Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. (PubMed, Focus (Am Psychiatr Publ)) - "In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1·19-1·96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least efficacious drugs (0·51-0·84). For acceptability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable than other antidepressants (range of ORs 0·43-0·77), whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine had the highest dropout rates (1·30-2·32)...These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants. National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science.Appeared..."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Electroacupuncture targets D-serine-related synaptic deficits in CUMS rats through modulating the astrocytic USP4/CB1R axis. (PubMed, Brain Res Bull) - "This study demonstrates that the astrocytic USP4/CB1R regulatory node in the hippocampal CA1 region is a critical pathological hub underlying CUMS-induced synaptic dysfunction. Mechanistically, CB1R stability is regulated by USP4-mediated deubiquitination, and the CB1R-dependent PLC/IP₃/D-serine signaling cascade functions as a glial checkpoint for synaptic homeostasis. EA exerts its antidepressant effects by restoring this checkpoint, thereby rescuing synaptic structure and function."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry • Targeted Protein Degradation • FAP • GFAP • USP4